FY2020 Financial Results

from the beginning

FY2020 Financial Results

• Speakers

• Forward Looking Statements

• CORE PRINCIPLE and WORLD VISION

• Agenda

1.Vision 2020 Review

• Vision 2020 Highlights

• From Vision 2020 to Santen 2030

@

• Solidify Core Businesses for MTP2025

2.FY2020 Results

• FY2020 Consolidated Results (YoY): Revenue - Core OP

• FY2020 Consolidated Results (YoY): Core OP - Net Profit

• Sales in FY2020 (YoY)

• Profit in FY2020 (YoY)

• Share by Region

3.FY2021 Business Plan, and Key Growth Drivers

• FY2021 Forecast

• FY2021 Sales Forecast (YoY)

• Japan

• China

• Asia

• EMEA

• Americas

• Profits (FY2019 - FY2021)

• Investing to Grow

• Pipeline: Main progress in FY2020 and outlook for FY2021

4.Direction for MTP2025

• Evolution from Vision 2020 to Santen 2030

• Management Themes to be Addressed in Next MTP

• Concepts Behind Mid-/Long-term Targets

• Capital Policy and Direction on Shareholder Return

• Dividend Forecast for FY2021

• Transition to a Holding Company and Accounting Period

5.R&D Update

• R&D Highlights

• Q4 FY2020 Topic - Strengthening the core business to address by LoE

@

• Q4 FY2020 Topic - new growth potential

@

• Current Status of Research and Development Main pipeline / product development (1)

• Current Status of Research and Development Main pipeline / product development (2)

• Current Status of Research and Development Main pipeline / product development (3)

Appendix

• FY2020 Consolidated Results (vs Forecasts as of May 8th, 2020)

• FY2020 Financial Position Changes

• Cash Flow Changes

• STN2000100 (DE-128) Impairment Loss

• Revenue / Contribution Profit by Region 1

• Revenue / Contribution Profit by Region 2

• FY2020 Revenue by Region

• Prescription Ophthalmic Market in Japan (Apr. 2020-Mar. 2021)

Q&A

Q&A 1

@

@

@

Q&A 2

@

@

@

@

Q&A 3

@

@

@

Q&A 4

@

@

@

Q&A 5

@

Q&A 6

@

@

@

@

Q&A 7

@

@